TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145

Benzinga Newsdesk www.benzinga.com Positive 78.5%

Neg 0% Neu 0% Pos 78.5%

TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $125 to $145.